Sage's depression drug moves closer to approval, shares soar

Adjust Comment Print

30 funds opened positions while 53 raised stakes. Its down 3.35% from 119,300 shares previously. Emerald Advisers Pa holds 182,804 shares. (NASDAQ:SAGE). Alps Advsrs invested 0.02% in Sage Therapeutics, Inc. Victory Cap Management holds 445,485 shares or 0.08% of its portfolio. Oppenheimer Asset accumulated 0% or 379 shares. Tocqueville Asset Lp reported 71,450 shares stake. TIAA CREF Investment Management LLC boosted its position in shares of SAGE Therapeutics by 15.5% in the third quarter. (NASDAQ:SAGE). State Street Corp owns 1.21 million shares for 0.01% of their portfolio. (NASDAQ:SAGE). 41,250 were reported by Rmb Cap Ltd Limited Liability Company. Jpmorgan Chase & Com holds 0.01% or 818,671 shares in its portfolio.

Sage Therapeutics (NASDAQ:SAGE) had its price target hoisted by stock analysts at Leerink Swann from $123.00 to $246.00 in a report issued on Thursday. This technical setup was reported by Barchart.com.


Trading stocks at an all time highs is usually a winning strategy. About 6.95M shares traded or 716.67% up from the average. Sage is also developing the drug-a once-daily pill that targets a neurotransmitter called GABA-for Parkinson's disease, essential tremor, and postpartum depression. It has outperformed by 99.75% the S&P500. SAGE Therapeutics had 44 analyst reports since September 3, 2015 according to SRatingsIntel.

SAGE has been the topic of several other research reports. The stock decreased 0.70% or $0.0099 during the last trading session, reaching $1.4101. The biopharmaceutical company reported ($1.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.61) by $0.09. State Street stated it has 0.01% of its portfolio in Sage Therapeutics, Inc. Therefore 88% are positive. Checking some other stock price data, we can see that the recent distance from the 50 day high was noted at 59.74% and the separation from the 50 day low is presently 169.50%. Needham maintained the stock with "Buy" rating in Tuesday, September 12 report. On Thursday, November 9 the stock rating was maintained by Cowen & Co with "Buy". (NASDAQ:SAGE) earned "Buy" rating by Canaccord Genuity on Tuesday, September 12. One analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The firm has "Neutral" rating given on Wednesday, February 22 by H.C. Wainwright. Stifel Nicolaus initiated it with "Buy" rating and $90 target in Monday, November 14 report. The rating was maintained by Leerink Swann on Tuesday, June 20 with "Buy". The results waned from their mid-stage results, but investors backed the notion that Sage has something important in a field marked by repeated setbacks.


Sage Therapeutics (NASDAQ:SAGE) last announced its quarterly earnings data on Thursday, November 2nd. "(SAGE) Is Soaring To A New High On Study Results" on December 07, 2017. (NASDAQ:SAGE) were released by: Schaeffersresearch.com and their article: "SAGE Therapeutics Options Traders Don't Buy Depression Drug Breakout" published on December 07, 2017 as well as Nasdaq.com's news article titled: "Mid-Day Market Update: Duluth Holdings Drops Following Q3 Results; SAGE ..." with publication date: December 07, 2017. More interesting news about Sage Therapeutics, Inc. Royal Bank Of Canada's price target would indicate a potential upside of 79.18% from the company's current price. The Company's lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor. It now has negative earnings.

Drug developer Sage Therapeutics Inc's shares soared as much as 85 percent to a record high on Thursday after its experimental drug to reduce the symptoms of depression succeeded in a mid-stage trial.


Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Comments